Profile data is unavailable for this security.
About the company
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and active pharmaceutical ingredients (APIs). It produces a comprehensive, diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. The Company's vertically integrated network enables it to produce a wide range of pharmaceuticals, including oncology, hormones, peptides, and steroidal drugs. The Company also has a product portfolio in RoW markets, including injectables, hospital products and retail products. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, Yonsa, Sezaby and Sprinkle portfolio.
- Revenue in INR (TTM)484.97bn
- Net income in INR95.76bn
- Incorporated1993
- Employees41.00k
- LocationSun Pharmaceutical Industries LtdSun House, CTS No. 201 B/1,, Western ExpMUMBAI 400 093IndiaIND
- Phone+91 2 243244324
- Fax+91 2 243244343
- Websitehttps://sunpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | 200.11bn | 19.14bn | 731.27bn | 18.97k | 38.29 | 5.12 | 23.35 | 3.65 | 41.89 | 41.89 | 437.85 | 313.60 | 0.8524 | 1.41 | 4.36 | -- | 8.24 | 1.43 | 13.34 | 2.22 | 66.80 | 59.70 | 9.67 | 2.04 | 0.9991 | 8.64 | 0.1689 | 79.28 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Aurobindo Pharma Ltd | 290.02bn | 31.73bn | 737.70bn | 15.69k | 23.26 | 2.47 | 15.73 | 2.54 | 54.12 | 54.12 | 494.54 | 509.35 | 0.6827 | 1.38 | 6.25 | -- | 7.46 | 9.24 | 10.35 | 13.43 | 56.54 | 54.15 | 10.93 | 12.72 | 1.18 | 16.12 | 0.1821 | -- | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | -- |
| Mankind Pharma Ltd | 103.35bn | 19.13bn | 897.66bn | 18.47k | 46.98 | 9.59 | 38.36 | 8.69 | 47.69 | 47.69 | 257.65 | 233.73 | -- | -- | -- | -- | -- | -- | -- | -- | 68.94 | -- | 18.79 | -- | 2.37 | 116.65 | 0.0212 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Torrent Pharmaceuticals Ltd | 107.28bn | 16.56bn | 975.43bn | 13.57k | 58.89 | 14.23 | 39.59 | 9.09 | 48.94 | 48.94 | 317.04 | 202.56 | 0.7135 | 1.19 | 5.66 | -- | 11.01 | 8.34 | 17.25 | 13.03 | 74.96 | 72.01 | 15.44 | 13.17 | 0.6141 | 7.23 | 0.3697 | 53.04 | 11.52 | 6.93 | 32.99 | 30.57 | -8.16 | 26.93 |
| Dr Reddy's Laboratories Ltd | 280.11bn | 55.78bn | 1.01tn | 24.83k | 18.19 | 3.59 | 14.38 | 3.62 | 334.61 | 334.61 | 1,680.33 | 1,696.70 | 0.7874 | 1.46 | 3.67 | -- | 15.68 | 11.37 | 21.05 | 16.02 | 70.69 | 66.52 | 19.91 | 14.63 | 1.92 | 41.27 | 0.0662 | 16.40 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Zydus Lifesciences Ltd | 195.47bn | 38.37bn | 1.12tn | 23.03k | 29.27 | 5.63 | 24.29 | 5.71 | 37.91 | 38.14 | 193.16 | 197.11 | 0.7103 | 1.82 | 4.06 | -- | 13.92 | 9.05 | 19.29 | 14.01 | 68.14 | 62.16 | 19.60 | 14.33 | 1.51 | 22,696.00 | 0.0351 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Divi's Laboratories Ltd | 78.45bn | 16.00bn | 1.22tn | 16.95k | 76.13 | 8.98 | 61.58 | 15.53 | 60.27 | 60.27 | 295.54 | 511.21 | 0.5246 | 1.01 | 3.97 | -- | 10.70 | 16.55 | 11.62 | 18.22 | 60.11 | 57.95 | 20.40 | 26.38 | 5.08 | -- | 0.0002 | 34.33 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
| Cipla Ltd | 257.74bn | 41.22bn | 1.26tn | 26.62k | 30.67 | 4.73 | 24.27 | 4.90 | 51.02 | 51.02 | 319.08 | 330.77 | 0.829 | 1.70 | 5.84 | -- | 13.37 | 10.09 | 16.16 | 12.40 | 65.78 | 59.69 | 16.12 | 12.66 | 2.71 | 58.30 | 0.0205 | 20.79 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Sun Pharmaceutical Industries Ltd | 484.97bn | 95.76bn | 3.64tn | 41.00k | 37.99 | 5.71 | 29.80 | 7.50 | 39.90 | 39.90 | 202.02 | 265.35 | 0.5836 | 1.05 | 4.28 | -- | 11.61 | 7.77 | 15.75 | 10.85 | 78.01 | 72.30 | 19.89 | 14.23 | 1.98 | 51.55 | 0.0465 | 39.86 | 10.51 | 10.78 | 13.01 | 29.15 | -7.28 | 37.47 |
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 31 May 2024 | 86.09m | 3.59% |
| Life Insurance Corporation of India (Investment Portfolio)as of 13 Sep 2023 | 72.27m | 3.01% |
| SBI Funds Management Ltd.as of 31 May 2024 | 53.37m | 2.23% |
| The Vanguard Group, Inc.as of 09 May 2024 | 42.48m | 1.77% |
| BlackRock Fund Advisorsas of 09 May 2024 | 26.06m | 1.09% |
| Norges Bank Investment Managementas of 30 Sep 2023 | 24.70m | 1.03% |
| GQG Partners LLCas of 31 Mar 2024 | 23.48m | 0.98% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 May 2024 | 19.73m | 0.82% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 May 2024 | 18.21m | 0.76% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 May 2024 | 16.27m | 0.68% |
